Table 2.

TRIAL I. Average Admission (A) and monthly values for Lipids: Cholesterol (CHOL), Triglycerides (TRGL), High Density Lipoproteins (HDL) and Low Density Lipoproteins (LDL) levels at four sampling times (Month Model)1 and Placebo (P) versus Maca-GO (M) contrast (Treatment Model) for two application sequences: APMM (n=18) and AMMP (n=18) during three months long study^a

Measurement	Treatment	Admission (A)	End of Month 1	End of Month 2	End of Month 3	SEDb	Placebo	Maca	SED	Pc
CHOL(mg/100ml)	APMM	255.2	234.5	224.1	218.6	10.53	234.5	222.3	8.1	ns
	AMMP	236.9	236.0	226.9	238.6	7.87	238.6	231.6	6.9	ns
	SED		15.13	15.17	16.3		14.43	14.53
	P		ns	ns	ns		ns	ns
TRGL (mg/100ml)	APMM	130.0	125.2A	107.2AB	83.8B	19.7*	125.2	98.8	15.5	ns
	AMMP	137.4	130.5	123.7	129.7	14.5	129.7	127.0	12.3	ns
	SED		26.4	26.63	28.4		24.7	25.3
	P		ns	ns	ns		ns	<0.05
HDL (mg/100ml)	APMM	67.07	59.54B	62.63AB	73.02A	5.39*	59.54	65.68	3.91	ns
	AMMP	61.54	66.38AB	69.83A	62.65B	3.13*	62.65B	68.07A	2.7	<0.05
	SED		5.42	5.73	6.62		5.07	5.42
	P		ns	ns	ns
LDL (mg/100ml)	APMM	187.7	171.7	165.0	149.5	13.8	171.7	157.2	9.8	ns
	AMMP	169.2	166.8	155.2	170.6	8.0	170.6	160.7	7.1	ns
	SED		15.1	16.1	18.6		14.4	15.4
	P		ns	ns	ns		ns	ns

^aFor explanation see Table 1;

^bStandard error of differences;

Asterisk (*) indicates existence of significant differences between monthly measurements within the same treatment sequence group. Values marked with unlike capital letters are considered statistically significant at P<0.05;

^cSignificance probabilities: ns = not significant at P>0.05; P<0.05 = significance at 5% probability level; P<0.01 = significance at 1% probability level; P<0.001 = significance at 0.1% probability level.